HBS Health 6th Annual Conference

Conference Co-Chairs:
Anula Jayasuriya, MD, MBA '93

Wolfgang Klietmann, MD, OPM 12, Vice President


			Kenneth S. Abramowitz, MBA '76 Managing General Partner, NGN Capital (New Global Network) Kenneth Abramowitz joined NGN from The Carlyle Group in New York where he was Managing Director, focused on U.S. buyout opportunities in the healthcare industry. Prior to that, Mr. Abramowitz was an Analyst at Sanford C. Bernstein & Co. covering the medical-supply, hospital-management and HMO industries, and an EGS Securities Healthcare Fund Manager. He has published notable studies and journal articles on topics including healthcare service companies, major medical mergers and cardiovascular device innovation. Mr. Abramowitz earned a BA from Columbia University in 1972 and an MBA from Harvard Business School in 1976. He sits on the Board of Directors of Power Medical Interventions, EKOS Corporation, and Option Care.
			David J. Brailer, MD, PhD National Coordinator for Health Information Technology, Department of Health and Human Services David Brailer heads the nation’s move toward widespread deployment of health information technology. Previously, he was a Senior Fellow at the Health Technology Center in San Francisco, CA. For 10 years he was Chairman and CEO of CareScience, Inc., a leading provider of care management services and Internet-based solutions. He earned his MD at West Virginia University and his PhD in managerial economics at The Wharton School, and completed his residency at the Hospital of the University of Pennsylvania. He received the first National Library of Medicine Martin Epstein Award, was a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania, and served on the Board of Trustees of the American Medical Association.

			Paula Cobb, MBA '00 Director, Commercial Operations, Biogen Idec International Paula Cobb is an International commercial director for Biogen Idec, where she’s part of a small team managing all aspects of Biogen’s International neurology business, as well as business development deals, collaborations, and international organization. She’s worked with Biogen since 2003, and moved to Switzerland at the beginning of 2004 to relocate Biogen Idec’s International headquarters to Zug. Previously she was a consultant at the Boston Consulting Group, and prior to that worked with the boutique consultancy Treacy & Company, and with Gemini Consulting. She received a BA from Amherst College cum laude, and an MBA from HBS.
			Earl M. Collier, Jr. Executive Vice President, Genzyme Corporation Earl M. Collier is executive vice president of Genzyme Corporation. He is responsible for managing Genzyme’s oncology and cardiovascular businesses. He joined Genzyme full-time in 1997, but his relationship with the company dates to 1990, when he began working with Genzyme as an outside lawyer. At Genzyme he was also president of Genzyme Biosurgery and its predecessor, Genzyme Surgical Products. He has more than 20 years of experience in healthcare, and sits on the board of The Covalent Group, Inc., Excigen Inc., Newton-Wellesley Hospital and Pervasis Therapeutics. He earned a BA at Yale University and a JD at the University of Virginia Law School.


			Robert A. DeNoble, MBA '72 President and CEO, The Marino Foundation for Integrative Medicine, Inc. President, Harvard Business School Health Industry Alumni Association Robert DeNoble has over 25 years of experience as a senior executive of healthcare organizations and as a consultant to health care providers and early stage biotech companies. In addition to his role as CEO of the Marino Foundation, he serves as a principal with RDA Healthcare Consulting, Inc., a company he co-founded to provide strategic, operational and financial management services to healthcare organizations. Prior to his current positions, he held senior positions with KPMG, LLP, Rhode Island Hospital, and McLean Hospital. He serves on the Board of the Austen Riggs Center, a national renowned psychiatric hospital located in western Massachusetts.

			Beatrice Ellerin, MBA '95 Managing Director, Interbrand Wood Founder, Past President, and Chairman, HBS Health Industry Alumni Association Beatrice Ellerin, known as Bunny, recently joined Interbrand Wood, a leading branding agency which provides brand consulting exclusively to the healthcare industry. She heads up rxmark, focused on brand research, and works closely with senior management to drive business growth. Previously Bunny was Executive Director of PPD Online Marketing & Education, Inc., where she directed corporate strategy, business development and global marketing. Earlier in her healthcare career, she was a Vice President at Vivra Specialty Partners, where she managed risk contracts and clinical data reporting for 14 single specialty networks. She received a BA in Political Science from Columbia University. As Chairman, Founder and past President of HBS Health, Bunny led the group's growth into a major HBS alumni association.

			Mark C. Fishman, MD President, Novartis Institutes for BioMedical Research Member of the Executive Committee of Novartis AG Mark Fishman leads all worldwide discovery research activities of Novartis in the US, Europe, and Japan. He was previously Professor of Medicine at Harvard Medical School, and Chief of Cardiology and Director of the Cardiovascular Research Center at the Massachusetts General Hospital. Dr. Fishman, contemporaneously with Dr. Nusslein-Volhard, introduced the zebrafish as a genetic model system for vertebrate development. He also authored the best-selling medical textbook, Medicine. A graduate of Yale College and Harvard Medical School, Dr. Fishman completed his Internal Medicine Residency, Chief Residency, and Cardiology training at the Massachusetts General Hospital. He serves on several editorial boards and is a member of the American Academy of Arts and Sciences.

			Richard G. Hamermesh, MBA '71, DBA '76 Professor of Management Practice Harvard Business School Richard Hamermesh teaches in the MBA Program and is the Faculty Chair of the HBS Healthcare Initiative. From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. From 1976 to 1987, he was a member of the faculty of the Harvard Business School. Richard is also an investor and entrepreneur, having participated as a principal, director, and investor in the founding and early stages of over 20 organizations. He was the founding president of the Newton (MA) Schools Foundation and served on the editorial board of the Harvard Business Review. Richard's best-known book, Fad-Free Management, was published in 1996. Richard received his BA from the University of California, and his MBA and DBA from HBS.


			Scott Hensley Staff Journalist, The Wall Street Journal Scott Hensley, a reporter in The Wall Street Journal's New York bureau, covers health care and the pharmaceutical industry. He writes "Follow the Money," a column giving a behind-the-scenes look at what drives decisions in the health-care industry, which appears on The Wall Street Journal Online at wsj.com. He also appears on CNBC, a cable news channel. Born in Texas, Mr. Hensley earned a bachelor's degree in natural sciences from Johns Hopkins University and a master's degree from Columbia University's Graduate School of Journalism. Before becoming a journalist, Mr. Hensley worked for Siemens Medical Systems, a medical equipment maker, for 10 years.
			Robert S. Huckman, PhD Assistant Professor, Harvard Business School Robert Huckman is an Assistant Professor at Harvard Business School and a faculty research fellow of the National Bureau of Economic Research. His research focuses on the linkages between organizational characteristics, technological choice, and operating performance, with an emphasis on the healthcare industry. He received a PhD in Business Economics from Harvard University and an AB in Public Policy, summa cum laude, from Princeton University, where he was elected to Phi Beta Kappa. Previously, he was a Principal and Founding Equity Member of Stamos Associates, Inc., a strategy and operations consulting firm serving clients in the healthcare industry which was later acquired by Perot Systems, Inc. He was also an Associate at Booz·Allen & Hamilton, Inc.

			Anula Jayasuriya, MD, PhD, MBA '93 Founding Partner, LifeScience-India Fund Co-Chair, HBS Health 6th Annual Healthcare Conference Anula Jayasuriya is a founding partner of Life-Science India, an affiliate fund of Draper Fisher Jurvetson, which invests in US companies that are leveraged by performing core strategic functions in India. She was previously a partner with Skyline Ventures, and prior to that with the German–US venture capital firm TVM. She has been VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche. She received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital. Besides her MBA with distinction from HBS, she also holds a MPhil in pharmacology from the University of Cambridge, England. She serves on the Board of HBS Health.

			William Jessee, MD, FACMPE, FACPM President and CEO, Medical Group Management Association (MGMA) William Jessee has served as President and Chief Executive Officer of the Medical Group Management Association (MGMA), the nation’s leading voice for group medical practice, since 1999. He also is Clinical Professor of Preventive Medicine and Biometrics at the University of Colorado Health Sciences Center, and Adjunct Professor of Health Policy and Administration at the University of North Carolina School of Public Health.A graduate of Stanford University and the University of California, San Diego School of Medicine, he took residency training in pediatrics at Indiana University Hospitals and completed his training in preventive medicine at the University of Maryland Hospital.

			Jerome P. Kassirer, MD Distinguished Professor, Tufts University School of Medicine Jerome Kassirer is Distinguished Professor at Tufts University School of Medicine and Adjunct Professor of Medicine and Bioethics at Case Western Reserve University. He was Editor-in-Chief of the New England Journal of Medicine between 1991 and 1999. He is the recipient of numerous awards and several honorary degrees, and a member of the Institute of Medicine of the National Academy of Sciences, the Association of American Physicians, and the American Academy of Arts and Sciences. Kassirer’s latest book is On The Take: How Medicine’s Complicity With Big Business Can Endanger Your Health, by Oxford Press.
			Wolfgang Klietmann, MD, OPM 12 President and Medical Director, Mediconsulting, Inc. Co-Chair, HBS Health 6th Annual Healthcare Conference Wolfgang Klietmann heads an international healthcare consulting company and is an appoined Lecturer in Pathology at Harvard Medical School. Previously on staff of the Department of Pathology at Massachusetts General Hospital, he also performed research as an Associate Scientist at the Wistar Institute of the University of Pennsylvania, headed a research group at the Max-Planck-Institute for Virus Research, and served on the medical faculty of the University of Tuebingen. He was Founder and Physician-in-Chief of a leading Institute of Laboratory Medicine in Germany. He received his medical education at the University of Freiburg (Germany), and at the Sorbonne and the University of Paris Medical School (France). He is a Fellow of the College of American Pathologists.

			Jay O. Light Acting Dean, Harvard Business School Dwight P. Robinson, Jr. Professor of Business Administration Jay Light, a distinguished member of the HBS faculty for 35 years, has held a number of senior leadership roles and is currently Senior Associate Dean, Director of Planning and Development. Previously, he served as Chairman of the Finance Area, and Senior Associate Dean, Director of Faculty Planning at HBS, and he has taught extensively in the MBA and Executive Education programs. He is currently a Director of the Harvard Management Company, a Director of Partners HealthCare (the Mass General and Brigham & Women's Hospitals) and the Chairman of the Investment Committee of Partners HealthCare. He is a graduate of Cornell University and Harvard University.

			Joseph B. Martin, MD, PhD Dean of the Harvard Faculty of Medicine Joseph B. Martin, MD, PhD, Caroline Shields Walker Professor of Neurobiology and Clinical Neuroscience, is Dean of the Harvard Faculty of Medicine. He served for four years as Dean of the School of Medicine at UCSF and as Chancellor. Dr. Martin received his MD from the University of Alberta in 1962, completed a neurology residency and a neuropathology fellowship at Case Western, and received his PhD in anatomy from the University of Rochester in 1971. His research focused on hypothalamic regulation of pituitary hormone secretions and on application of neurochemical and molecular genetics to better understand the causes of neurological and neurodegenerative disease.

			Stephen N. Oesterle, MD Senior Vice President for Medicine and Technology, Medtronic, Inc. Stephen Oesterle provides executive leadership for Medtronic scientific research, formation of technological strategies and continued development of strong cooperative relationships with the world's medical communities. He was previously Associate Professor of Medicine at the Harvard University Medical School and Director of Invasive Cardiology Services at Massachusetts General Hospital, Boston. A world-recognized clinician, teacher and innovator in the field of cardiac catheterization, he developed and directed interventional cardiology programs at Good Samaritan Hospital, Los Angeles; at Georgetown University; and at Stanford University. He has been an advisor and consultant to medical device companies, financial institutions and Internet service providers. A summa cum laude graduate of Harvard College, he received his MD from Yale University.

			Michael E. Porter, PhD, MBA '71 University Professor, Harvard Business School Michael Porter is the Bishop William Lawrence University Professor at the Institute for Strategy and Competitiveness, based at the Harvard Business School. He is a leading authority on competitive strategy and international competitiveness. The author of 16 books and over 100 articles, Professor Porter has led competitiveness initiatives in various nations and states, guides regional projects in Central America and the Middle East, and is co-chairman of the Global Competitiveness Report. He founded the Initiative for a Competitive Inner City, a non-profit private sector initiative formed to catalyze business development in distressed inner cities across the U.S. Professor Porter is a holder of eight honorary doctorates.

			Una S. Ryan, PhD, OBE President and CEO, AVANT Immunotherapeutics, Inc. Una Ryan leads Avant Immunotherapeutics, Inc., a publicly traded Massachusetts biotechnology company developing vaccines and immunotherapeutics for large high value markets including cardiac surgery, cholesterol management, infectious diseases, biodefense and food safety. She is also Research Professor of Medicine at Boston University School of Medicine, serves on the Board of the Biotechnology Industry Organization and the Whitehead Institute Board of Associates, and is Chair of the Massachusetts Biotechnology Council. In 2002, Her Majesty Queen Elizabeth II awarded her the Order of the British Empire (OBE) for her services to research, development and promotion of biotechnology.

			Marcus Sasse, MD Senior Healthcare Analyst and Strategist, UBS Global Asset Management, Zurich, Switzerland Marcus Sasse is a Senior Healthcare Analyst and Strategist at UBS Global Asset Management. He is part of the Equity Portfolio Management Global Team, where he is responsible for the UBS (Lux) Biotech Fund and for Healthcare Equity Research. After graduating from medical school, he started a residency in Orthopedic Surgery at the University of Basel, Switzerland, which he finished with the board certification. After leading a Research Project at the University of Calgary, Canada, he worked for a Healthcare Investment Company as an analyst before joining UBS. He holds an MD from the University of Aachen, Germany and an MBA from Kellogg University.
			Ronald Scott Chief Financial Officer, Basilea Pharmaceutica AG, Basel, Switzerland Prior to joining Basilea, Ronald Scott was director at the Prudential Investment Corporation in the U.S. working in Prudential's Finance and International Business Development Units where he managed divestitures and joint venture transactions. He also worked nine years at F. Hoffmann-La Roche, Basel, Switzerland, in management positions in Pharmaceutical Finance, Licensing and Roche Corporate Finance Mergers and Acquisitions. His assignments included managing Roche's call, primary and secondary offerings of Genentech shares; Roche's biotechnology investment portfolio; acquisitions; and divestitures. He played a key role in the founding of Basilea and is a member of the Basilea Board of Directors.

			David P. Terry, MBA '98 Senior Vice President of Business Development, Harborside Healthcare Vice President, Harvard Business School Health Industry Alumni Association At Harborside, David Terry leads the long-term care compay’s efforts to acquire and grow new ancillary business lines. Prior to joining Harborside, he was the Director of Product Management for Partners Community Healthcare Incorporated, the for-profit physician network arm of the Partners Healthcare system. He has been Vice President of Operations for Citizens Energy Corporation and a Senior Associate with APM Incorporated, a healthcare consulting firm. He holds an MBA from Harvard Business School and a BA from Columbia University.

			Christoph von Arb, PhD Consul General of Switzerland and Director, Swiss House for Advanced Research and Education (SHARE), Cambridge, MA Christoph von Arb has been Consul General and Director of the first Science Consulate of Switzerland called SHARE in Boston since 2002. Before, he was Head of International Affairs in the Office of the State Secretary for Education and Research and negotiated Switzerland’s full participation in the EU-Research Framework Program. In 2001, he was a visiting Fellow at VBI at Virginia Tech. From 1990 until 1995 he was Counselor for Science and Technology at the Embassy of Switzerland in Washington, D.C. leaving the Swiss Federal Science and Technology Council after three years. He received his PhD in Molecular Biology in 1984 from the University of Berne. Dr. von Arb is a frequent lecturer at various Universities in Boston.


			Josef H. von Rickenbach, MBA '81 Founder, Chairman, and CEO, PAREXEL International Corporation Josef von Rickenbach heads PAREXEL, one of the world's largest bio/pharmaceutical outsourcing companies providing expertise-based product development and marketing outsourcing services to the international pharmaceutical, biotechnology, and medical device industries. His management of the company's expansion was recognized when he was named the Ernst & Young New England Region Entrepreneur of the Year in 1997. He began his career with Schering-Plough, then held positions with ENSECO (formerly ERCO). He currently serves as Chairman of the Association of Clinical Research Organizations (ACRO). He holds a Bachelor of Business Administration from the Lucerne College of Industry Economics and Administration in Switzerland and an MBA from Harvard University.

			Andreas Wicki, PhD CEO, HBM BioVentures AG, Zug, Switzerland Andreas Wicki, a healthcare entrepreneur and investor, currently heads HBM BioVentures, a leading investment company with a life science focus. He has over 17 years of experience in the pharma and biotechnology industry and has been advising APAX and Bank Vontobel on their private equity investments in that sector since 1992. Previously, he was co-owner and CEO of ANAWA Laboratorien AG, and Senior Vice President of European Analytical Operations of MDS Pharma Services. He was also the founder and CEO of Clinserve AG, a clinical trial services company. He holds an MS and a PhD in chemistry and biochemistry from the University of Berne, Switzerland.
			Janet Woodcock, MD Acting Deputy Commissioner for Operations, US Food and Drug Administration Washington, DC Currently Acting Deputy Commissioner for Operations at FDA, Janet Woodcock, MD has served as Director, Center for Drug Evaluation and Research at FDA since 1994. She previously served in other positions in FDA including Director, Office of Therapeutics Research and Review and Acting Deputy Director, Center for Biologics Evaluation and Research. She received her MD from Northwestern Medical School, and completed further training and held faculty appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.